stockrow
Friday 6 November 2026
Export RPRX’s income statement to Excel — free account
Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
67.15
0.42
−0.62%
Follow RPRX
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 6 | 5 | 5 |
+8 more TTM periods Free account |
| 0.00% | 8.42% | 8.38% | 7.69% | ||
| 0.00% | 4.26% | 4.42% | 4.07% | ||
ROIC |
5.24% | 5.28% | 5.43% | 5.41% | |
Return on Tangible Assets |
0.00% | 4.69% | 4.74% | 4.51% | |
Average Days of Receivables |
0.00 | 4.53 | 4.11 | 4.50 | |
Free Cash Flow per Share |
6.64 | 2.94 | 2.74 | 5.79 | |
Free Cash Flow |
2,959.92 | 1,310.08 | 1,195.57 | 2,489.82 | |
Capital Expenditures |
— | (1,666.37) | (1,416.41) | — | |
| Other line items | |||||
Cash ROIC |
15.64% | 6.69% | 6.13% | 12.90% | |
Accounts Receivable Turnover |
0.00 | 85.65 | 95.15 | 84.52 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.60% | 9.41% | 18.08% | 19.01% | |
Selling, General and Administrative Expense of Revenue |
24.29% | 23.83% | 25.50% | 24.11% | |
Share Based Compensation of Revenue |
17.57% | 16.86% | 16.86% | 12.19% | |
Interest Coverage |
4.02 | 4.19 | 4.73 | 5.07 | |
Operating CF/Net income |
0.00 | 3.67 | 3.16 | 3.23 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (46.64) | (39.29) | 0.00 | |
Revenue per Share |
5.87 | 5.70 | 5.59 | 5.53 | |
Operating CF per Share |
6.64 | 6.69 | 5.98 | 5.79 | |
Capex per Share |
0.00 | (3.74) | (3.24) | 0.00 | |
Capex to Sales |
0.00 | 0.66 | 0.58 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026